1. Home
  2. CELU vs PLUR Comparison

CELU vs PLUR Comparison

Compare CELU & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$0.86

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Logo Pluri Inc.

PLUR

Pluri Inc.

N/A

Current Price

$2.31

Market Cap

36.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CELU
PLUR
Founded
2016
2001
Country
United States
Israel
Employees
123
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.2M
36.3M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
CELU
PLUR
Price
$0.86
$2.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$6.00
$12.00
AVG Volume (30 Days)
112.8K
10.8K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.78
EPS
N/A
N/A
Revenue
N/A
$1,336,000.00
Revenue This Year
N/A
$97.38
Revenue Next Year
$76.00
$293.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
309.82
52 Week Low
$0.71
$2.22
52 Week High
$4.35
$5.96

Technical Indicators

Market Signals
Indicator
CELU
PLUR
Relative Strength Index (RSI) 42.23 32.16
Support Level $0.71 N/A
Resistance Level $1.44 $3.49
Average True Range (ATR) 0.06 0.31
MACD 0.02 -0.12
Stochastic Oscillator 64.72 16.07

Price Performance

Historical Comparison
CELU
PLUR

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: